ATRA on XNAS, Health Care, Atara Biotherapeutics, Inc, job postings
Measures activity, not value. Not investment advice.
Revenue fell 97% to $4M while insiders bought $1M of stock and shares are down 52% in a year.
BadNet loss $14.6M over 12 months against cash of $9.9M
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.2M, net loss $2.2M.
31 Dec 2021RevenueNet incomeNet losstallest bar $98.1M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$1.2M
-$2.2M
30 Jun 2026
$630K
-$4.8M
31 Mar 2026
$516K
-$4.1M
31 Dec 2025
–
-$3.4M
30 Sep 2025
$3.5M
-$4.3M
30 Jun 2025
$17.6M
$2.4M
31 Mar 2025
$98.1M
$38.0M
31 Dec 2024
$32.8M
-$12.7M
30 Sep 2024
$40.2M
-$21.9M
30 Jun 2024
$28.6M
-$19.0M
31 Mar 2024
$27.4M
-$31.8M
31 Dec 2023
$4.3M
-$60.5M
30 Sep 2023
$2.1M
-$69.8M
30 Jun 2023
$957K
-$71.1M
31 Mar 2023
$1.2M
-$74.8M
31 Dec 2022
–
-$74.6M
30 Sep 2022
$4.5M
-$84.1M
30 Jun 2022
$51.6M
$18.5M
31 Mar 2022
$7.3M
-$88.1M
31 Dec 2021
–
-$93.3M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$4.0M
$151.9M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-97%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$14.6M
$23.4M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.12
$3.64
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-344%
17.3%
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-369%
15.4%
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
-$69.8M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$9.9M
$13.7M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
16.3
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
–
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$920K
bought $1.0M, sold $80K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-2.8%
35 13F filers vs 36
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
45%
4.6M shares held by 13F filers (30 Sep 2026) of 10.2M outstanding (6 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
2.9%
297K shares sold short (30 Oct 2026) of 10.2M outstanding (6 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
13.4
297K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-15%
350K shares sold short in the report before, 297K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
53%
53% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 47%
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$20K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
14
14 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
14 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.
Price $6.33 on 20 Nov 2026, -52% over 12 months (12-month range $4.18 to $18.09)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $1.9M in the last 12 months (the 12 months before: $663K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.Revenue per quarter. Revenue $1.2M in the latest quarter, -65% on a year earlier.Capital spending per quarter. Capital spending $0 in the latest quarter, -100% on a year earlier.Institutional holders (13F filers). 35 13F filers reported holding it in the latest 13F quarter, -2.8% on a year earlier.Lobbying spend. Lobbying spend: $20K published in the last 12 months, -67% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Mar 2022: $7.3M; public on 9 May 2023
Quarter ended 30 Jun 2022: $51.6M; public on 9 Aug 2023
Quarter ended 30 Sep 2022: $4.5M; public on 2 Nov 2023
Quarter ended 31 Mar 2023: $1.2M, -83% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $957K, -98% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $2.1M, -52% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $4.3M; public on 29 Mar 2024
Quarter ended 31 Mar 2024: $27.4M, +2131% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $28.6M, +2893% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $40.2M, +1780% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $32.8M, +670% on a year earlier; public on 8 Mar 2025
Quarter ended 31 Mar 2025: $98.1M, +259% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $17.6M, -39% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $3.5M, -91% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Mar 2026: $516K, -99% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $630K, -96% on a year earlier; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $1.2M, -65% on a year earlier; public on 11 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $2.5M, +310% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $2.6M, +19% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $1.4M, -31% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $132K, -97% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Mar 2023: $399K, -85% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $499K, -65% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $281K, +113% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $44K; public on 29 Mar 2024
Quarter ended 31 Mar 2024: $127K, -68% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $29K, -94% on a year earlier; public on 13 Aug 2024
Quarter ended 31 Dec 2024: $90K, +105% on a year earlier; public on 8 Mar 2025
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $0, -100% on a year earlier; public on 17 Mar 2026
Institutional holders (13F filers)
31 Dec 2021 report: 125; public on 14 Feb 2022
31 Mar 2022 report: 137; public on 16 May 2022
30 Jun 2022 report: 125; public on 15 Aug 2022
30 Sep 2022 report: 146; public on 14 Nov 2022
31 Dec 2022 report: 130; public on 14 Feb 2023
31 Mar 2023 report: 117; public on 15 May 2023
30 Jun 2023 report: 108; public on 14 Aug 2023
30 Sep 2023 report: 100; public on 14 Nov 2023
31 Dec 2023 report: 84; public on 14 Feb 2024
31 Mar 2024 report: 79; public on 15 May 2024
30 Jun 2024 report: 46; public on 14 Aug 2024
30 Sep 2024 report: 34; public on 14 Nov 2024
31 Dec 2024 report: 43; public on 14 Feb 2025
31 Mar 2025 report: 35; public on 15 May 2025
30 Jun 2025 report: 31; public on 14 Aug 2025
30 Sep 2025 report: 36; public on 14 Nov 2025
31 Dec 2025 report: 40; public on 17 Feb 2026
31 Mar 2026 report: 33; public on 15 May 2026
30 Jun 2026 report: 36; public on 14 Aug 2026
30 Sep 2026 report: 35; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $60K published
Quarter from 1 Apr 2022: $60K published
Quarter from 1 Jul 2022: $60K published
Quarter from 1 Oct 2022: $60K published
Quarter from 1 Jan 2023: $60K published
Quarter from 1 Apr 2023: $60K published
Quarter from 1 Jul 2023: $60K published
Quarter from 1 Oct 2023: $60K published
Quarter from 1 Jan 2024: $60K published
Quarter from 1 Apr 2024: $30K published
Quarter from 1 Jul 2024: $30K published
Quarter from 1 Oct 2024: $30K published
Quarter from 1 Jan 2025: $30K published
Quarter from 1 Apr 2025: $30K published
Quarter from 1 Jul 2026: $10K published
Quarter from 1 Oct 2026: $10K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is lobbying spend reported (quarter) at $10K (30 Sep 2026), 67% below its normal reading of $30K; higher than 11% of its own history.
Reported lobbying spend: $10K in Q3 2026, $10K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
3 Apr 2026
New
Jeffrey J. Kimbell & Associates, Inc.for Atara Biotherapeutics, Inc.
Issues related to regulation of cell therapiesHealth issues
had 1.0M shares sold short in the 15 Jan 2026 report, 1.9× the same report last year.
Same report last year: 548K; its normal report is 267K.
See the evidence
This period
1.0M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
267K
Typical spread (median absolute deviation)
104K
How far from its usual level
+4.8
Same report last year
548K
History used
2,939 days
the 15 Jan 2026 report24 earlier reportsnormal: 267K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $98.1M for the quarter ended 31 Mar 2025, 3.6× the same quarter last year.
Same quarter last year: $27.4M; its normal quarter is $15.8M.
See the evidence
This period
$98.1M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$15.8M
Typical spread (median absolute deviation)
$14.1M
How far from its usual level
+3.9
Same quarter last year
$27.4M
History used
1,096 days
the quarter ended 31 Mar 20258 earlier quartersnormal: $15.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $32.8M for the quarter ended 31 Dec 2024, 7.7× the same quarter last year.
Same quarter last year: $4.3M; its normal quarter is $4.4M.
See the evidence
This period
$32.8M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$4.4M
Typical spread (median absolute deviation)
$3.3M
How far from its usual level
+5.9
Same quarter last year
$4.3M
History used
1,006 days
the quarter ended 31 Dec 20248 earlier quartersnormal: $4.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $40.2M for the quarter ended 30 Sep 2024, 19× the same quarter last year.
Same quarter last year: $2.1M; its normal quarter is $4.4M.
See the evidence
This period
$40.2M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$4.4M
Typical spread (median absolute deviation)
$3.3M
How far from its usual level
+7.4
Same quarter last year
$2.1M
History used
914 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $4.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $28.6M for the quarter ended 30 Jun 2024, 30× the same quarter last year.
Same quarter last year: $957K; its normal quarter is $4.4M.
See the evidence
This period
$28.6M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$4.4M
Typical spread (median absolute deviation)
$3.0M
How far from its usual level
+5.4
Same quarter last year
$957K
History used
822 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $4.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $27.4M for the quarter ended 31 Mar 2024, 22× the same quarter last year.
Same quarter last year: $1.2M; its normal quarter is $4.3M.
See the evidence
This period
$27.4M (the quarter ended 31 Mar 2024)
Normal quarter (median of 7 earlier)
$4.3M
Typical spread (median absolute deviation)
$3.0M
How far from its usual level
+5.2
Same quarter last year
$1.2M
History used
731 days
the quarter ended 31 Mar 20247 earlier quartersnormal: $4.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Showing the newest 40 of 93 entries; narrow the window or the kind of data to see older ones.
Not listed: 442 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it